Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
DFTX

Definium Therapeutics (DFTX) stock: insider trades, news & valuation

Heavy selling
Close · Oct 9, 2026 $36.90 +8.0% on the day +195.2% over 12 months 52-week range $10.68 – $48.45

Share price and insider trades

DFTX closeInsider buyInsider sale
0204060NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $561,071 on 2025-12-26 · Daniel Karlin, Mark Sullivan, Robert BarrowSold $721,733 on 2026-09-03 · Robert BarrowSold $796,999 on 2026-03-25 · Daniel Karlin, Mark Sullivan, Robert BarrowSold $2,301,277 on 2026-09-25 · Brandi Roberts, Daniel Karlin, Mark Sullivan, Matthew T. Wiley, Robert BarrowSold $2,617,639 on 2026-06-25 · Brandi Roberts, Daniel Karlin, Mark Sullivan, Matthew T. Wiley, Robert Barrow
Bought, 12 months$0
Sold, 12 months$7.0M
Insiders buying0
Insiders selling5

Definium Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $7.0M of DFTX stock on the open market.

DFTX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $561K sold (3 trades)Q4 2025Q1 2026: $797K sold (3 trades)Q1 2026Q2 2026: $2.6M sold (5 trades)Q2 2026Q3 2026: $3.0M sold (6 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0$3.0M6
Q2 2026—0$2.6M5
Q1 2026—0$797K3
Q4 2025—0$561K3

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —

Summary

Over the past 12 months, 0 Definium Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $7.0M. 17 of 17 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 29SEC Robert BarrowCEO Sell Plan 31,5502,213,090 held (−1%) $36.57 $1.2M +0.9% —
Sep 29SEC Mark SullivanGeneral Counsel Sell Plan 14,051494,228 held (−3%) $36.57 $514K +0.9% —
Sep 29SEC Daniel KarlinChief Medical Officer Sell Plan 10,853792,846 held (−1%) $36.57 $397K +0.9% —
Sep 29SEC Brandi RobertsCFO Sell Plan 3,377394,528 held (−1%) $36.57 $123K +0.9% —
Sep 29SEC Matthew T. WileyChief Commercial Officer Sell Plan 3,097359,036 held (−1%) $36.57 $113K +0.9% —
Sep 4SEC Robert BarrowCEO Sell Plan 19,0231,494,640 held (−1%) $37.94 $722K -2.7% —
Jun 26SEC Robert BarrowCEO Sell Plan 29,2081,098,246 held (−3%) $45.03 $1.3M -18.1% —
Jun 26SEC Mark SullivanGeneral Counsel Sell Plan 13,008320,571 held (−4%) $45.03 $586K -18.1% —
Jun 26SEC Daniel KarlinChief Medical Officer Sell Plan 10,035503,282 held (−2%) $45.03 $452K -18.1% —
Jun 26SEC Brandi RobertsCFO Sell Plan 3,013209,487 held (−1%) $45.03 $136K -18.1% —
Jun 26SEC Matthew T. WileyChief Commercial Officer Sell Plan 2,867174,633 held (−2%) $45.03 $129K -18.1% —
Mar 26SEC Robert BarrowCEO Sell Plan 24,431752,454 held (−3%) $18.47 $451K +99.8% —
Mar 26SEC Mark SullivanGeneral Counsel Sell Plan 10,702271,079 held (−4%) $18.47 $198K +99.8% —
Mar 26SEC Daniel KarlinChief Medical Officer Sell Plan 8,018413,317 held (−2%) $18.47 $148K +99.8% —
Dec 29SEC Robert BarrowCEO Sell Plan 25,791778,477 held (−3%) $13.15 $339K +180.6% —
Dec 29SEC Mark SullivanGeneral Counsel Sell Plan 11,276282,576 held (−4%) $13.15 $148K +180.6% —
Dec 29SEC Daniel KarlinChief Medical Officer Sell Plan 5,600425,025 held (−1%) $13.15 $74K +180.6% —

Insiders at Definium Therapeutics, Inc.

InsiderBoughtSoldLast filingScore
Robert BarrowCEO — $4.0M Sep 29, 2026 —
Mark SullivanGeneral Counsel — $1.4M Sep 29, 2026 —
Daniel KarlinChief Medical Officer — $1.1M Sep 29, 2026 —
Brandi RobertsCFO — $259K Sep 29, 2026 —
Matthew T. WileyChief Commercial Officer — $242K Sep 29, 2026 —

DFTX stock: common questions

Are Definium Therapeutics, Inc. insiders buying DFTX stock?

In the past 12 months, 0 insiders reported open-market purchases of DFTX worth $0.

Are Definium Therapeutics, Inc. insiders selling DFTX stock?

5 insiders reported sales worth $7.0M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is DFTX's 52-week range?

Over the past year DFTX has traded between $10.68 and $48.45. It last closed at $36.90 on Oct 9, 2026.